Sunmax Biotechnology Co., Ltd. (TPEX: 4728)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
276.00
-0.50 (-0.18%)
Dec 19, 2024, 12:36 PM CST
36.97%
Market Cap 14.92B
Revenue (ttm) 1.74B
Net Income (ttm) 698.95M
Shares Out 54.46M
EPS (ttm) 12.82
PE Ratio 21.37
Forward PE n/a
Dividend 11.00 (4.01%)
Ex-Dividend Date Jul 17, 2024
Volume 3,199
Open 280.50
Previous Close 276.50
Day's Range 276.00 - 280.50
52-Week Range 191.50 - 350.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 27, 2025

About Sunmax Biotechnology

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4728
Full Company Profile

Financial Performance

In 2023, Sunmax Biotechnology's revenue was 1.69 billion, an increase of 20.64% compared to the previous year's 1.40 billion. Earnings were 625.71 million, an increase of 17.21%.

Financial Statements

News

There is no news available yet.